Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report

Abstract

to a shift in the immune response promoting Th1/Th17 polarization.Therefore, the use of dupilumab in genetically predisposed individuals may be a trigger event towards the development or worsening of Th1/Th17 related diseases, such as psoriasis 6 and MS. This case is the second reporting the onset of MS after initiation of dupilumab: Laageide et al. described the onset of similar symptoms just 2 months after initiation of dupilumab. 7 Further studies are needed to better understand if dupilumab can increase the risk of MS onset or flareups. Meanwhile we recommend caution in prescribing dupilumab in patients with MS or a family history of MS.